Global DNA Diagnostics Market is Expected to Reach Nearly $36.5 Billion by 2018
News Apr 29, 2013
Biomarkers are playing increasingly important roles, and one disease area, cancer, is getting much attention in this regard. Technologies such as DNA microarrays are being used to analyze biological samples in molecular diagnostics to identify high-risk patients, predict response to therapy, and monitor patients during treatment to either determine effectiveness of treatment or detect recurrence of disease. Numerous companies are developing molecular oncology diagnostics tests.
In 2012, the global DNA diagnostics market was valued at more than $17.3 billion. The total market is projected to grow at a compound annual growth rate (CAGR) of 12.6% from 2013 through 2018 to reach nearly $36.5 billion by 2018.
Within the global DNA diagnostics market, the market for polymerase chain reaction-based diagnostic assays claimed the largest share in 2012 with an estimated $8.3 billion. The PCR diagnostics market is projected to grow at a five-year CAGR of 11.5% to reach $16.3 billion by 2018.
The fastest-growing segment of the DNA diagnostics market is the biochip/lab-on-a-chip (LOAC) market, which was valued at $1.7 billion in 2012. It is projected to increase at a CAGR of 17% to reach $4.6 billion by 2018. The market for microarray diagnostic assays was valued at $3.9 billion in 2012 and is projected to grow at a CAGR of 12.4% to reach $8.2 billion by 2018. The market for in situ hybridization diagnostic assays was valued at nearly $3.3 billion in 2012 and is projected to increase at a CAGR of 12.8% to reach nearly $7.1 billion by 2018.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE